Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BNTC Benitec Biopharma

Trading 04-13 10:54:48 EDT

11.47

+0.05

+0.39%

High11.63	Low11.26	Vol12.31K
Open11.40	D1 Closing11.42	Amplitude3.20%
Mkt Cap392.73M	Tradable Cap239.05M	Total Shares34.25M
T/O140.62K	T/O Rate0.06%	Tradable Shares20.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BNTC","market":"US","secType":"STK","nameCN":"Benitec Biopharma","latestPrice":11.465,"timestamp":1776091991754,"preClose":11.42,"halted":0,"volume":12306,"delay":0,"changeRate":0.0039404553415061236,"floatShares":20850800,"shares":34254907,"eps":-1.055337,"marketStatus":"Trading","change":0.045,"latestTime":"04-13 10:54:48 EDT","open":11.4,"high":11.625,"low":11.26,"amount":140616.699468,"amplitude":0.031961,"askPrice":11.7,"askSize":100,"bidPrice":11.34,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-1.055337,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776110400000},"marketStatusCode":2,"adr":1,"adrRate":200,"listingDate":1439870400000,"exchange":"NASDAQ","adjPreClose":11.42,"postHourTrading":{"tag":"盘后","latestPrice":11.42,"preClose":11.42,"latestTime":"17:55 EDT","volume":2253,"amount":25729.04,"timestamp":1775858113616,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.577102,"impliedVol":0.1769,"impliedVolPercentile":0.064},"requestUrl":"/m/hq/s/BNTC/tweets","defaultTab":"tweets","newsList":[{"id":"2618193411","title":"Benitec Biopharma to host MDA conference industry forum breakfast on BB-301 OPMD trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618193411","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618193411?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:03","pubTimestamp":1773140639,"startTime":"0","endTime":"0","summary":"Benitec will host an Industry Forum Breakfast and presentation at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026. The event is scheduled for 7:00 a.m. to 8:00 a.m. ET at the Hilton Orlando in the Key Largo Room. Materials include a presentation available here.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL1n0fgz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","SG9999014021.USD","BK4112","BK4585","IE00BKPKM429.USD","LU2095319765.USD","BK4139","BNTC","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618678778","title":"Benitec Biopharma Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618678778","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618678778?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:30","pubTimestamp":1773073800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BNTC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 12:30 ET (16:30 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640291","title":"Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640291","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640291?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251690/0/en/Benitec-Biopharma-Announces-Positive-Interim-Phase-1b-2a-Results-for-High-Dose-BB-301-and-Continued-Durable-Improvements-for-Low-Dose-BB-301-Treatment-at-the-2026-Muscular-Dystroph.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2413666426.HKD","BK4588","LU0225283273.USD","LU2089279066.USD","LU0070302665.USD","IE00BN0W2V16.EUR","BK4202","IE00BN0W2W23.USD","BK4547","LU0310800965.SGD","BK4139","BK4121","A","LU0320765489.SGD","LU0963586101.USD","LU1543694498.USD","MDA","LU0208291251.USD","LU2092937221.SGD","LU2041044095.USD","LU0052756011.USD","BK4567","BK4585","BK4516","LU0128525689.USD","BNTC","LU2413666699.HKD","LU1721428933.USD","LU1267930227.SGD","LU1165135440.EUR","LU0347712357.USD","IE00BN0W2T93.GBP","TPR","BK4097","LU2229751404.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613781816","title":"Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613781816","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613781816?lang=en_us&edition=fundamental","pubTime":"2026-02-23 20:01","pubTimestamp":1771848111,"startTime":"0","endTime":"0","summary":"Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLbV5d7q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BNTC","NDAQ","BK4588","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","BK4139","SG9999014013.SGD","BK4112","BK4585","IE00B64PRP62.GBP","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611155620","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2611155620","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611155620?lang=en_us&edition=fundamental","pubTime":"2026-02-13 19:00","pubTimestamp":1770980400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Adv. Auto Parts                                  4Q       .41   6:30 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRSP","BLCO","BRSP","FLR","DFIN","ACLS","FELE","BBNX","ALLE","CDNS","ANDE","BLDR","ET","SMWB","EQT","CEVA","ESNT","FE","BNTC","CIGI","CE","AWK","AAP","CRNT","ATMU","ENLT","EXE","CSR","AMRZ","ARR","ADAM","CZR","BHC","CAR","AERO","CCJ","CNH","ETOR","BELFB","ENB","DCH","AGI","AMPL","DTE","ADI","ESI","ATRC","ACCO","BELFA","DVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610922835","title":"Benitec Biopharma Q2 EPS $(0.26) Misses $(0.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2610922835","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610922835?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:07","pubTimestamp":1770905253,"startTime":"0","endTime":"0","summary":"Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by 16.59 percent. This is unchanged from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50575762/benitec-biopharma-q2-eps-0-26-misses-0-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610066921","title":"Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2610066921","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610066921?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:36","pubTimestamp":1770903390,"startTime":"0","endTime":"0","summary":"“We continue to be encouraged by the benign safety profile and the durability of efficacy demonstrated in our BB-301 clinical development program,”...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-reports-q2-eps-26c-vs-26c-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-reports-q2-eps-26c-vs-26c-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610219529","title":"BRIEF-Benitec Biopharma Q2 Operating Income USD -13.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2610219529","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610219529?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:30","pubTimestamp":1770903046,"startTime":"0","endTime":"0","summary":"BRIEF-Benitec Biopharma Q2 Operating Income USD -13.4 Million\n\n\nFeb 12 (Reuters) - Benitec Biopharma Q2 net income USD -11.8 million.\n\nQ2 EPS USD -0.26","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nPLX034972:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610692196","title":"Benitec Biopharma Q2 EPS USD -0.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2610692196","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610692196?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:30","pubTimestamp":1770903001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nPLX034972:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610921138","title":"Press Release: Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2610921138","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610921138?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:30","pubTimestamp":1770903000,"startTime":"0","endTime":"0","summary":"-The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301-. -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint-. - An update on the Interim clinical results for Cohort 2 is planned for mid-2026-. -FDA meeting to formalize the pivotal BB-301 study design expected mid-year-. \"We continue to be encouraged by the benign safety profile and the durability of efficacy demonstrated in our BB-301 clinical development program,\" said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BNTC","BK4139","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610292949","title":"Benitec Biopharma posts Q2 net loss of USD 11.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2610292949","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610292949?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:10","pubTimestamp":1770901853,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc. reported its financial results for the second quarter  ended December 31, 2025. The company reported a net loss attributable to shareholders of USD 11.8 million, or USD 0.26 per basic and diluted share, for the quarter. Loss from operations for Q2 was USD 13.4 million. Benitec Biopharma ended the period with USD 189 million in cash and cash equivalents. In terms of business updates, Benitec Biopharma highlighted progress in its BB-301 clinical development program. The first four patients enrolled in Cohort 1 of the BB-301 Phase 1b/2a treatment study completed the 12-month statistical follow-up period, with all four classified as formal responders at the 12-month mark, demonstrating a durable response to the therapy. The first patient completed a 24-month follow-up, continuing to show improvements in post-swallow residue and overall dysphagic symptom burden compared to the 12-month results. An update on interim clinical results for Cohort 2 is scheduled for mid-20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL5yds5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607463021","title":"Benitec Biopharma files to sell 1.48M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2607463021","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607463021?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:05","pubTimestamp":1769807117,"startTime":"0","endTime":"0","summary":"The company will not receive any of the proceeds from the sale of the common stock by the selling stockholders. Published first on TheFly – the ult...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-files-to-sell-1-48m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-files-to-sell-1-48m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602155969","title":"Benitec Biopharma Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602155969","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602155969?lang=en_us&edition=fundamental","pubTime":"2026-01-11 21:00","pubTimestamp":1768136435,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc. announced positive long-term results from its Phase 1b/2a clinical trial evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dystrophy . The company reported that the first patient in Cohort 1 completed a 24-month post-treatment assessment, showing continued improvements in post-swallow pharyngeal residue and total dysphagic symptom burden compared to earlier timepoints. Additionally, all four patients in Cohort 1 completed the 12-month statistical follow-up period and met the pre-specified criteria for response to BB-301, demonstrating a durable response. Benitec Biopharma plans to engage with the U.S. Food and Drug Administration in mid-2026 to confirm the pivotal study design and will continue to present interim clinical results at future medical conferences.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL3wndQx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","SG9999014013.SGD","NDAQ","SG9999014021.USD","BK4588","SG9999014005.SGD","LU2210149790.SGD","BK4585","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014039.USD","BK4139","IE00BGHQF748.EUR","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602559576","title":"Benitec Biopharma Provides Positive Long-Term Clinical Study Results for Bb-301 Phase 1B/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2602559576","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602559576?lang=en_us&edition=fundamental","pubTime":"2026-01-11 21:00","pubTimestamp":1768136403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA4JKMGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602531478","title":"Benitec Biopharma Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia","url":"https://stock-news.laohu8.com/highlight/detail?id=2602531478","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602531478?lang=en_us&edition=fundamental","pubTime":"2026-01-11 07:50","pubTimestamp":1768089056,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc. has released a new presentation detailing the development of BB-301, a genetic medicine candidate for the treatment of Oculopharyngeal Muscular Dystrophy -related dysphagia. BB-301 employs a single-vector approach that combines gene silencing of the mutant PABPN1 gene with the delivery of a functional, healthy gene. The therapy is administered directly to the pharyngeal constrictor muscles through intramuscular injection, aiming to restore normal muscle function by blocking the production of the harmful protein while supplying a new, functional version. The presentation highlights BB-301's clinical progress, including a 100% responder rate in Cohort 1 and ongoing pivotal study planning. The candidate has been granted Fast Track and Orphan Drug Designations from regulatory agencies. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL8Kgtlm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595751575","title":"Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595751575","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595751575?lang=en_us&edition=fundamental","pubTime":"2025-12-30 08:32","pubTimestamp":1767054727,"startTime":"0","endTime":"0","summary":"Suvretta Capital Management, LLC has reported the acquisition of common shares of Benitec Biopharma Inc. , according to a recent SEC Form 4 filing. The form was filed by more than one reporting person, including Suvretta Capital Management, LLC and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL5Sm03R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593510284","title":"Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593510284","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593510284?lang=en_us&edition=fundamental","pubTime":"2025-12-23 08:45","pubTimestamp":1766450739,"startTime":"0","endTime":"0","summary":"Suvretta Capital Management, LLC has reported the acquisition of common shares of Benitec Biopharma Inc. , according to a recent SEC filing. The form was filed by more than one reporting person, including Suvretta Capital Management, LLC and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDLnJz19:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588061200","title":"Benitec Biopharma Inc. held annual stockholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588061200","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588061200?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:28","pubTimestamp":1764714494,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc. held its 2025 Annual Meeting of Stockholders on December 1, 2025. Stockholders elected Dr. Jerel Banks and Megan Boston to the board of directors. The appointment of the independent registered public accounting firm was ratified. All proposals brought before the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL23s8v4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585462784","title":"Benitec Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462784?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:16","pubTimestamp":1763990160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BNTC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 08:16 ET (13:16 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584320926","title":"Benitec Biopharma Announces Pricing Of $100 Million Common Stock Offering At $13.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2584320926","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584320926?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:44","pubTimestamp":1763570644,"startTime":"0","endTime":"0","summary":"Nov 6 (Reuters) - Benitec Biopharma Inc ::*BENITEC BIOPHARMA INC. ANNOUNCES PRICING OF $100 MILLION COMMON STOCK OFFERING*BENITEC BIOPHARMA INC - EACH SHARE OF COMMON STOCK IS BEING SOLD AT AN OFFERIN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD12l9sh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.benitec.com","stockEarnings":[{"period":"1week","weight":0.0458},{"period":"1month","weight":-0.07},{"period":"3month","weight":-0.0355},{"period":"6month","weight":-0.2346},{"period":"1year","weight":-0.0436},{"period":"ytd","weight":-0.1522}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.034036},{"month":2,"riseRate":0.545455,"avgChangeRate":0.090462},{"month":3,"riseRate":0.727273,"avgChangeRate":0.04636},{"month":4,"riseRate":0.454545,"avgChangeRate":0.030254},{"month":5,"riseRate":0.4,"avgChangeRate":-0.050483},{"month":6,"riseRate":0.2,"avgChangeRate":-0.131553},{"month":7,"riseRate":0.5,"avgChangeRate":0.061416},{"month":8,"riseRate":0.4,"avgChangeRate":-0.00465},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.108578},{"month":10,"riseRate":0.636364,"avgChangeRate":-0.026473},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.075117},{"month":12,"riseRate":0.545455,"avgChangeRate":-0.032403}],"exchange":"NASDAQ","name":"Benitec Biopharma","nameEN":"Benitec Biopharma","securityTypeName":"DR","adrRate":"1:200"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Benitec Biopharma,BNTC,Benitec Biopharma股票,Benitec Biopharma股票老虎,Benitec Biopharma股票老虎国际,Benitec Biopharma行情,Benitec Biopharma股票行情,Benitec Biopharma股价,Benitec Biopharma股市,Benitec Biopharma股票价格,Benitec Biopharma股票交易,Benitec Biopharma股票购买,Benitec Biopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction